Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Hepatocellular 20Nasopharyngeal Carcinoma 12Triple Negative Breast Neoplasms 11Esophageal Neoplasms 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Hodgkin Disease 5Recurrence 4Colorectal Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Advanced Gastric Cancer 3Respiratory Tract Diseases 2Rectal Neoplasms 2Osteosarcoma 2Neoplasms 2Nasopharyngeal Neoplasms 2Metastatic Gastric Adenocarcinoma 2Lymphoma, Extranodal NK-T-Cell 2Lung Diseases 2

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Borderline Resectable Pancreatic Cancer × camrelizumab × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡